Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates

Drug Metabolism and Disposition

Volumn 32, Issue 10, 2004, Pages 1111-1120

  Balakin, Konstantin V ^a   Ekins, Sean ^b,c   Bugrim, Andrey ^b   Ivanenkov, Van A ^a   Korolev, Dmitry ^a   Nikolsky, Yuri V ^b   Ivashchenko, Andrey A ^a   Savchuk, Nikolay P ^a   Nikolskaya, Tatiana ^b  

^a CHEMDIV INC   (United States)

^b GeneGo bioinformatics software Inc   (United States)

^c GeneGo   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLMETHADOL; ALVAMELINE; AMINOPHENAZONE; AMIODARONE; AMODIAQUINE; AZELASTINE; BENZPHETAMINE; CAFFEINE; CISAPRIDE; CLOZAPINE; DEXTROMETHORPHAN; DIAZEPAM; DILTIAZEM; DISOPYRAMIDE; EBASTINE; IMIPRAMINE; KETAMINE; LIDOCAINE; LILOPRISTONE; METHYLPHENOBARBITAL; METOCLOPRAMIDE; MIFEPRISTONE; MIRTAZAPINE; NORTRIPTYLINE; ONAPRISTONE; PIMOZIDE; SERTRALINE; THEOPHYLLINE; TOLTERODINE; UNINDEXED DRUG;

ARTICLE; CORRELATION COEFFICIENT; DEALKYLATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; MODEL; NERVE CELL NETWORK; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REACTION TIME; RISK ASSESSMENT; XENOBIOTIC METABOLISM;

CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; HUMANS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4644322438     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.000364     Document Type: Article

References (69)

1. Agrafiotis DK and Lobanov VS (1997) Nonlinear mapping networks. J Chem Inf Comput Sci 40:1356-1362.
2. Agrafiotis DK, Myslik JC, and Salemme FR (1999) Advances in diversity profiling and combinatorial series design. Mol Divers 4:1-22.
3. Altomare C, Carrupt PA, Gaillard P, el Tayar N, Testa B, and Carotti A (1992) Quantitative structure-metabolism relationship analyses of MAO-mediated toxication of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and analogues. Chem Res Toxicol 5:366-375.
4. Andrea TA and Kalayeh H (1991) Applications of neural networks in quantitative structure-activity relationships of dihydrofolate reductase inhibitors. J Med Chem 34:2824-2836.
5. Balaban AT (1982) Highly discriminating distance-based topological index. Chem Phys Lett 89:399-404.
6. Balakin KV, Ekins S, Bulgrim A, Ivanenkov YA, Korolev D, Nikolsky YV, Skorenko AV, Ivashchenko AA, Savchuk NP, and Nikolskaya T (2004) Kohonen maps for prediction of human cytochrome P450 3A4. Drug Metab Dispos 32:1183-1189.
7. Bigus JP (1996) Data Mining with Neural Networks. McGraw-Hill, New York.
8. Bodor N (1999) Recent advances in retrometabolic design approaches. J Control Release 62:209-222.
9. Bollard ME, Holmes E, Blackledge CA, Lindon JC, Wilson ID, and Nicholson JK (1996) 1H and 19F-NMR spectroscopic studies on the metabolism and urinary excretion of mono- and disubstituted phenols in the rat. Xenobiotica 26:255-273.
10. Bouska JJ, Bell RL, Goodfellow CL, Stewart AO, Brooks CD, and Carter GW (1997) Improving the in vivo duration of 5-Lipoxygenase inhibitors: application of an in vitro glucuronosyl-transferase assay. Drug Metab Dispos 25:1032-1038.
11. Buchwald P (2001) Structure-metabolism relationships: steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev Med Chem 1:101-111.
12. Buchwald P and Bodor N (1999) Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem 42:5160-5168.
13. Bugrim A, Nikolskaya T, and Nikolsky Y (2004) Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov Today 9:127-135.
14. Cupid BC, Beddell CR, Lindon JC, Wilson ID, and Nicholson JK (1996) Quantitative structure-metabolism relationships for substituted benzoic acids in the rabbit: prediction of urinary excretion of glycine and glucuronide conjugates. Xenobiotica 26:157-176.
15. Darvas F (1988) Predicting metabolic pathways by logic programming. J Mol Graphics 6:80-86.
16. de Groot MJ, Ackland MJ, Horne VA, Alex AA, and Jones BC (1999) A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J Med Chem 42:4062-4070.
17. de Groot MJ and Ekins S (2002) Pharmacophore modeling of cytochromes P450. Adv Drug Delivery Rev 54:367-383.
18. Di Carlo FJ (1990) Structure-activity relationships (SAR) and structure-metabolism relationships (SMR) affecting the teratogenicity of carboxylic acids. Drug Metab Rev 22:411-449.
19. Di Carlo FJ, Bickart P, and Auer CM (1986a) Structure-metabolism relationships (SMR) for the prediction of health hazards by the Environmental Protection Agency. I. Background for the practice of predictive toxicology. Drug Metab Rev 17:171-184.
20. Di Carlo FJ, Bickart P, and Auer CM (1986b) Structure-metabolism relationships (SMR) for the prediction of health hazards by the Environmental Protection Agency. II. Application to teratogenicity and other toxic effects caused by aliphatic acids. Drug Metab Rev 17:187-220.
21. Echizen H, Tanizaki M, Tatsuno J, Chiba K, Berwick T, Tani M, Gonzalez FJ, and Ishizaki T (2000) Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos 28:937-944.
22. Ekins S (2003) In silico approaches to predicting metabolism, toxicology and beyond. Biochem Soc Trans 31:611-614.
23. Ekins S, Boulanger B, Swaan PW, and Hupcey MAZ (2002) Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J Comput-Aided Mol Des 16:381-401.
24. Ekins S, Bugrim A, Nikolsky Y, and Nikolskaya T (2004) Systems biology: applications in drug discovery, in Drug Discovery Handbook (Gad S ed) John Wiley & Sons, Inc., New York, in press.
25. Ekins S, de Groot M, and Jones JP (2001) Pharmacophore and three-dimensional quantitative structure-activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 29:936-944.
26. Ekins S, Stresser DM, and Williams JA (2003) In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 24:161-166.
27. Eldred DV, Weikel CL, Jurs PC, and Kaiser KLE (1999) Prediction of fathead minnow acute toxicity of organic compounds from molecular structure. J Med Chem 12:670-678.
28. Estabrook RW (1996) Cytochrome P450: from a single protein to a family of proteins-with some personal reflections, in Cytochromes P450: Metabolic and Toxicological Aspects (Ionnides and Parke eds) pp 4-28, CRC Press, Boca Raton, FL.
29. Feierman DE and Lasker JM (1996) Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos 24:932-939.
30. Gutman I, Ruscic B, Trinajstic N, and Wilcox CF Jr (1991) Graph theory and molecular orbitals. XII. Acyclic polyenes. J Chem Phys 62:3399-3405.
31. Hall LH and Kier LB (1991) The molecular connectivity chi indexes and kappa shape indexes in structure-property modeling. Rev Comput Chem 2:367-422.
32. Hayashi S, Watanabe J, and Kawajiri K (1991) Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem (Tokyo) 110:559-565.
33. Holmes E, Sweatman BC, Bollard ME, Blackledge CA, Beddell CR, Wilson ID, Lindon JC, and Nicholson JK (1995) Prediction of urinary sulphate and glucuronide conjugate excretion for substituted phenols in the rat using quantitative structure-metabolism relationships. Xenobiotica 25:1269-1281.
34. Humphreys WG, Obermeier MT, Barrish JC, Chong S, Marino AM, Murugesan N, Wang-Iverson D, and Morrison RA (2003) Application of structure-metabolism relationships in the identification of a selective endothelin A antagonist BMS-193884 with favourable pharmacokinetic properties. Xenobiotica 33:1109-1123.
35. Ioannides C and Parke DV (1996) Cytochromes P450: Metabolic and Toxicological Aspects. CRC Press, Boca Raton, FL.
36. Jones JP and Korzekwa KR (1996) Predicting the rates and stereoselectivity of reactions mediated by the P450 superfamily. Methods Enzymol 272:326-335.
37. Jones JP, Mysinger M, and Korzekwa KR (2002) Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen abstraction. Drug Metab Dispos 30:7-12.
38. Kato S, Onda M, Matsukura N, Tokunaga A, Tajiri T, Kim DY, Tsuruta H, Matsuda N, Yamashita K, and Shields PG (1995) Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Pharmacogenetics 5:141-144.
39. Korolev D, Balakin KV, Nikolsky Y, Kirillov E, Ivanenkov YA, Savchuk NP, Ivashchenko AA, and Nikolskaya T (2003) Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J Med Chem 46:3631-3643.
40. LeCun Y, Denker JS, Solla SA, and Touretzky D (1990) Advances in Neural Information Processing Systems, pp 598-605, Morgan Kaufmann, San Mateo, CA.
41. Lewis DF (2000) On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. Biochem Pharmacol 60:293-306.
42. Lewis DF, Modi S, and Dickins M (2002) Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev 34:69-82.
43. Lewis DFV, Eddershaw PJ, Dickins M, Tarbit MH, and Goldfarb PS (1998) Structural determinants of P450 substrate specificity. Chem-Biol Interact 115:175-199.
44. Madsen P, Ling A, Plewe M, Sams CK, Knudsen LB, Sidelmann UG, Ynddal L, Brand CL, Andersen B, Murphy D, et al. (2002) Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6- tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J Med Chem 45:5755-5775.
45. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, and Obach RS (2000) (R)-, (S)-, and racemic fluoxetine are metabolized by multiple human cytochrome P450 enzymes in vitro. Drug Metab Dispos 28:1187-1191.
46. McGinnity DF, Parker AJ, Soars M, and Riley RJ (2000) Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab Dispos 28:1327-1334.
47. Mimoto T, Terashima K, Nojima S, Takaku H, Nakayama M, Shintani M, Yamaoka T, and Hayashi H, (2004) Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2- methylbenzoyl-allophenylnorstatine structure. Bioorg Med Chem 12:281-293.
48. Mulder G (1990) Conjugation Reactions in Drug Metabolism. Taylor & Francis, London.
49. Nielsen KK, Flinois JP, Beaune P, and Brosen K (1996) The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 277:1659-1664.
50. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303-1310.
51. Projean D, Baune B, Farinotti JPF, Beaune P, Taburet A-M, and Ducharme J (2003) In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 31:748-754.
52. Rochat B, Amey M, Gillet M, Meyer UA, and Baumann P (1997) Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7:1-10.
53. Rohrbaugh RH and Jurs PC (1987) Descriptions of molecular shape applied in studies of structure/activity and structure/property relationships. Anal Chim Acta 199:99-109.
54. Rotzinger S and Baker GB (2002) Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes. Eur Neuropsychopharmacol 12:91-100.
55. Sammon JW (1969) A non-linear mapping for data structure analysis. IEEE Trans Comp C-18:401-409.
56. Singh SB, Shen LQ, Walker MJ, and Sheridan RP (2003) A model for likely sites of CYP3A4-mediated metabolism on drug-like molecules. J Med Chem 46:1330-1336.
57. Smith DA, Ackland MJ, and Jones BC (1997a) Properties of cytochrome P450 isoenzymes and their substrates. Part 1: Active site characteristics. Drug Discov Today 2:406-414.
58. Smith DA, Ackland MJ, and Jones BC (1997b) Properties of cytochrome P450 isoenzymes and their substrates. Part 2: properties of cytochrome P450 substrates. Drug Discov Today 2:479-486.
59. So SS and Karplus M (1997) Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications. J Med Chem 40:4360-4371.
60. So SS and Richards WG (1992) Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5- (substituted-benzyl)pyrimidines as DHFR inhibitors. J Med Chem 35:3201-3207.
61. Stanton DT and Jurs PC (1990) Development and use of charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies. Anal Chem 62:2323-2329.
62. Szklarz GD, Graham SE, and Paulsen MD (2000) Molecular modeling of mammalian cytochromes P450: application to study enzyme function. Vitam Harm 58:53-87.
63. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001) Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 297:326-337.
64. Vickers AE, Sinclair JR, Zollinger M, Heitz F, Glanzel U, Johanson L, and Fischer V (1999) Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 27:1029-1038.
65. Wessel MD, Jurs PC, Tolan JW, and Muskal SM (1998) Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sci 38:726-735.
66. Wiener H (1947) Structural determination of paraffin boiling points. J Am Chem Soc 69:17-20.
67. Wold S (1991) Validation of QSARs. Quant Struct-Act Relat 10:191-193.
68. Yan Z and Caldwell GW (2001) Metabolism profiling and cytochrome P450 inhibition and induction in drug discovery. Curr Top Med Chem 1:403-425.
69. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, and Iga T (2001) Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 29:887-890.